Bristol-Myers Squibb Company Delivers Excellent Second Quarter with Global New Product Approvals, Important Clinical Data and Strong Financial Results

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced double-digit sales growth in a quarter that was highlighted by important new product approvals in both the U.S. and Europe, and key data from the Company’s cardiovascular, oncology and diabetes franchises. In addition, the Company raised guidance for 2011 and confirmed minimum non-GAAP guidance for 2013.

MORE ON THIS TOPIC